Vyteris' Marketing Partner Launches LidoSite(R) in Hospitals across the U.S.

FAIR LAWN, N.J. -- Vyteris Holdings (Nevada), Inc. (OTCBB:VYHN) today announced that its marketing partner, B. Braun Medical Inc., kicked off the nationwide launch of the LidoSite(R) Topical System to hospitals during B. Braun's national sales meeting held on February 22-24, 2006 in Orlando, Florida. B. Braun will employ two sales teams totaling 85 people. Specifically, sales teams will focus on the IV Infusion and Hospital Pharmacy areas in U.S. hospitals.

"B. Braun is the perfect partner for selling to the 5,000 hospitals in the U.S. As a leading pain management and drug delivery company, its formidable sales force is second to none in this space," commented Timothy J. McIntyre, Vyteris' newly appointed chief executive officer.

Commenting on the national launch, Brad Lane, Vice President of Marketing, Pain Control Products for B. Braun, said, "We are very excited about the LidoSite(R) launch and the enthusiasm was evident during our sales meeting. This national launch is being built on a series of several highly successful product evaluations and trials at leading hospitals and institutions. We value the Vyteris partnership, and look forward to working together to improve patient care."

About B. Braun

Since its founding in 1839, B. Braun has built an unparalleled store of knowledge and expertise in delivering innovative healthcare products, medical devices and programs that enhance both patient and health-professional safety. Its 30,000 employees worldwide are proud of their commitment to translating customer needs into products with unmatched quality, superior technology, cost-effectiveness and environmental responsibility.

Through its "Sharing Expertise(R)" initiative, B. Braun promotes best practices for continuous improvement of healthcare products and services. For more information about B. Braun or its safety healthcare products, call 800-854-6851, email at [e-mail] or visit B. Braun at www.bbraunusa.com.

About Vyteris, Inc.

Vyteris Holdings (Nevada), Inc. is a specialty pharmaceutical company developing and manufacturing pharmaceutical products based upon its advanced drug delivery technology. The Company's Actyve(TM) transdermal technology delivers drugs comfortably through the skin using low-level electrical energy. This technology programs drug dosing, thus providing physicians and patients with precise control in the rate, dosage and pattern of delivery. The Company's LidoSite(R) product provides local analgesia for superficial dermatological procedures such as venipuncture, IV cannulation and laser ablation of superficial skin lesions. For more information, contact www.vyteris.com.

LidoSite is a registered trademark of B. Braun Medical Inc.

Actyve is a trademark of Vyteris Holdings (Nevada), Inc.

Forward-Looking Statements

Statements in this press release other than historical statements constitute "forward-looking statements". Such forward-looking statements are subject to material risks and uncertainties, which could cause the Company's forward-looking statements to be materially inaccurate. The Company has described such risks and uncertainties under the caption "Risk Factors" in various filings made with the SEC, including those contained in the Company's Form 10-Q for the quarter ended September 30, 2005.